Highest-materiality recent filing
MBX 4291 Phase 1 shows 7% mean weight loss at 8 weeks; MBX 5765 nominated
Preliminary blinded data: mean weight loss 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, incl. 2 placebo).
MBX Biosciences Q1 net loss $23.5M; Phase 3 canvuparatide start on track for Q3 2026
Cash, equivalents and marketable securities of $440M; expected to fund operations into 2029.
MBX Biosciences reports FY2025 net loss of $87M; Phase 3 canvuparatide on track for Q3 2026
Net loss FY2025 $87.0M vs $61.9M in 2024; R&D expenses $79.2M, up from $57.4M.
MBX Biosciences successful End-of-Phase 2 FDA meeting; Phase 3 trial for canvuparatide in Q3 2026
Phase 3 double-blind placebo-controlled trial will enroll ~160 patients; 3:1 randomization, 4-week fixed 600 ug dose then 18-week titration, 4-week maintenance.
MBX Biosciences CFO Richard Bartram resigns; John Smither named interim CFO
CFO Richard Bartram resigns effective March 15, 2026; will serve as consultant post-resignation.
MBX Biosciences raises ~$87.1M in ATM offering; 2.25M shares sold at $38.76 VWAP
Closed sale of 2,250,986 shares at a volume-weighted average price of $38.76 for gross proceeds of approximately $87.1 million on February 4, 2026.
MBX Biosciences appoints Laurie Stelzer as independent director and audit committee chair
Laurie Stelzer appointed as Class I director effective Jan. 20, 2026, filling an existing board vacancy.
MBX Biosciences reports $373.7M cash, expands obesity pipeline with two new candidates in 2026
Preliminary unaudited cash, cash equivalents and marketable securities of $373.7M at Dec 31, 2025; runway into 2029.
MBX posts positive Phase 2 results for canvuparatide; Q3 net loss $21.6M; cash $391.7M
Q3 2025 net loss $21.6M vs $18.1M YoY; cash and equivalents $391.7M (includes $200M offering proceeds) funding into 2029.
MBX Biosciences raises $187.5M via public offering of 11.1M shares at $18.00
Offering of 11,108,055 shares at $18.00 per share; underwriters have 30-day option for up to 1,666,208 additional shares.
Primary composite endpoint met: 63% (30/48) of canvuparatide patients vs 31% (5/16) placebo at Week 12 (p=0.042).
MBX Biosciences doses first participant in Phase 1 trial of obesity drug MBX 4291
Phase 1 trial is randomized, double-blind, placebo-controlled; Part A: 5 SAD cohorts (8 each, 3:1 randomization).
MBX Biosciences Q2 net loss $19.4M; cash $224.9M; canvuparatide Phase 2 data on track for Q3 2025
Net loss $19.4M for Q2 2025 vs $15.9M in Q2 2024; R&D expenses increased to $17.7M.
MBX Biosciences submits IND for MBX 4291, once-monthly GLP-1/GIP obesity prodrug
IND submitted to FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug for obesity.
Company posted updated corporate presentation on its website on June 9, 2025.
Stockholders elected Tiba Aynechi (24.3M for) and P. Kent Hawryluk (24.4M for) to three-year terms ending 2028.
Also effective as of June 5, 2025 was the departure of Carl L. Gordon, Ph.D., CFA from the Company's board of directors.
Max materiality 0.85 · Median 0.65 · Most common event other_material